Clinical trials
Metastatic Malignant Neoplasm in the Lung clinical trials
Below are recruiting metastatic malignant neoplasm in the lung clinical trials, each written for real people, not researchers. We’re tracking 114 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05963867RecruitingPhase 1
First-dose study of a cancer drug taken up by tumors
This Phase 1 study tests how BI 764532 moves into and through tumors in people with small-cell lung cancer or neuroendocrine cancer. It’s likely aimed at understanding the drug’s behavior in your body and tumor, especially if you’ve already tried standard treatments.
AmsterdamAges 18 years+ - NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT02885753RecruitingPhase 3
Liver-only metastatic colon cancer trial using targeted chemo
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
BrusselsAges 18 years+ - NCT07146646RecruitingPhase 2
Chemo combo for advanced bile duct cancer
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
Cleveland, OhioAges 19 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Bethesda, MarylandAges 18–120 - NCT04854213Recruiting
Study checks radiation effects in colon cancer lung-limited spread
This trial studies how targeted radiation (SBRT) affects cancer biology and immune cells in people with colon cancer that has spread only to a small number of lung nodules. Your tumor tissue will be analyzed to see what changes after treatment.
Naples, NAPOLIAges 18–80 - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT04633252RecruitingPhase 1/Phase 2
Study drug plus docetaxel and abiraterone for advanced prostate cancer
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Bethesda, MarylandAges 18–110 - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT05955105RecruitingPhase 1/Phase 2
ILB-2109 plus toripalimab for advanced solid cancers
This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.
Jinan, ShandongAges 18–80
Hear when a new Metastatic Malignant Neoplasm in the Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic malignant neoplasm in the lung?
- Yes. Clin2 currently lists 114 recruiting metastatic malignant neoplasm in the lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic malignant neoplasm in the lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic malignant neoplasm in the lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Malignant Solid Neoplasm
- Metastatic Malignant Neoplasm in the Brain
- Lung Neoplasm Malignant
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Malignant Neoplasm in the Peritoneum
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Leptomeninges
- Metastatic Malignant Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.